StockData
Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc. (LUCD) company profile

LUCDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3034% above fair value
$0.40+0.00 (+0.30%)

Close on Nov 17, 2026Market cap $81.09MP/E –Yield –

About Lucid Diagnostics

Surgical & Medical Instruments & Apparatus, SIC 3841

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company focused on preventing esophageal adenocarcinoma in patients with gastroesophageal reflux disease. Its core products include EsoCheck, a noninvasive swallowable balloon capsule catheter used for targeted esophageal cell sampling, and EsoGuard, a targeted next-generation sequencing DNA test designed to detect esophageal precancer. The company markets its diagnostic products to primary care and gastroenterology physicians, self-insured employers, unions, and healthcare systems, while also providing testing through commercial health network arrangements and a direct-to-consumer telemedicine program.

The company operates its own clinical laboratory in Lake Forest, California, along with dedicated physical Lucid Test Centers and satellite collection sites in physician offices. EsoCheck has received regulatory clearance in the United States and CE Mark certification in Europe, and cell collection devices are produced through third-party manufacturing partners. The text does not disclose the location of the corporate headquarters.

Summary of the business section of Lucid Diagnostics's latest annual report, written by StockData.

Company profile

Company

Legal name
Lucid Diagnostics Inc.
Founded
2018
Headquarters
New York, NY
Address
360 Madison Avenue, 25th Floor 10017
Phone
(212) 949-4319
Employees
82, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Marcum LLP, New York, NY

Stock & identifiers

Ticker
LUCD
Exchange
Nasdaq
IPO date
Oct 15, 2021
Shares outstanding
203M, Aug 10, 2026
Public float
$82.70M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1799011
CUSIP
54948X109
ISIN
US54948X1090
FIGI
BBG012NYMLC0
Share class FIGI
BBG012NYMM65
EIN
82-5488042

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Lishan AklogChief Executive Officer, Director3,636,627
Victoria Tou-ho LeeChief Medical Officer650,000
Dennis M. McGrathChief Financial Officer1,813,569
Shaun O'NeilPresident and COO1,446,763
Michael Adam GordonGeneral Counsel and Secretary1,000,000
Dennis MatheisDirector1,033,443
Debra WhiteDirector235,800
James L. CoxDirector405,120
Ronald M. SparksDirector320,460
John R. PalumboDirector338,000
Stanley LapidusDirector337,392
Jacque J. SokolovDirector320,460

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsTotalvs. prior year
Lishan Aklog
Chairman of the Board and Chief Executive Officer
$300.00K$150.00K$447.00K$897.00K+26%
Dennis M. McGrath
Chief Financial Officer
$225.00K$78.75K$447.00K$750.75K+18%
Shaun M. O’Neil
President and Chief Operating Officer
$300.00K$75.00K$447.00K$822.00K+15%
Michael A. Gordon
General Counsel and Corporate Secretary
$250.00K$62.50K$447.00K$759.50K+15%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 15, 2021
Offer price
$14.00
Securities offered
5,000,000
Gross proceeds
$70.00M
Exchange
Nasdaq
First trading day
Oct 14, 2021
First-day close
$11.76-16.0%
Lock-up ends (est.)
Apr 12, 2022

“Per Share Total Public offering price $ 14.00 $ 70,000,000 Underwriting discount (1) $ 0.98 $ 4,900,000 Proceeds to us, before offering expenses $ 13.02 $ 65,100,000 (1) See “Underwriting” beginning on page 146 of this prospectus for a description of the compensation payable to, and other arrangements with, the und”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 23, 2026 we have 82 employees (all of whom are full-time employees), inclusive of our executive officers – our Chairman of the Board of Directors and Chief Executive Officer (“CEO”), our President and Chief Operating Officer (“President” or “COO”), our Chief Financial Officer (“CFO”), our General Counsel and Secretary (“General”

Corporate history

Events identified from SEC filings

See a number that looks wrong?